

Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/TCE5A0E507C0EN.html>

Date: January 2020

Pages: 138

Price: US\$ 3,500.00 (Single User License)

ID: TCE5A0E507C0EN

Abstracts

Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2020

SUMMARY

According to the recently published report 'Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2020'; Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) pipeline Target constitutes close to 32 molecules.

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins.

The report 'Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2020' outlays comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or

Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 6, 1, 16 and 3 respectively. Report covers products from therapy areas Immunology, Dermatology, Gastrointestinal, Musculoskeletal Disorders, Oncology, Respiratory, Ophthalmology and Cardiovascular which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Inflammatory Bowel Disease, Alopecia Areata, Psoriasis, Ulcerative Colitis, Vitiligo, Asthma, Crohn's Disease (Regional Enteritis), Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Dermatomyositis, Diffuse Large B-Cell Lymphoma, Inflammation, Systemic Lupus Erythematosus, Allergic Conjunctivitis, Anaplastic Large Cell Lymphoma (ALCL), Androgenic Alopecia, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Autoimmune Disorders, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Cachexia, Celiac Disease, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Cutaneous T-Cell Lymphoma, Dermatitis (Eczema), Dermatoses, Fibrosis, Follicular Lymphoma, Ischemia Reperfusion Injury, Lung Transplant Rejection, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Myeloproliferative Disorders, Pemphigus Vulgaris, Peripheral T-Cell Lymphomas (PTCL), Polyarticular Juvenile Idiopathic Arthritis (PJIA), Pruritus, Psoriatic Arthritis, Sarcoidosis, Sarcopenia, Systemic Sclerosis (Scleroderma) and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Companies Involved in Therapeutics Development

Aclaris Therapeutics Inc

Arrien Pharmaceuticals LLC

Astellas Pharma Inc

Bristol-Myers Squibb Co

Chipscreen Biosciences Ltd

Clevexel Pharma SAS

Daewoong Pharmaceutical Co Ltd

Guangdong Zhongsheng Pharmaceutical Co Ltd

Japan Tobacco Inc

KBP BioSciences Co Ltd

Merck & Co Inc

MYOS RENS Technology Inc

Oncostellae SL

Pfizer Inc

Portola Pharmaceuticals Inc

Sienna Biopharmaceuticals Inc

Sincere Pharmaceutical Group

Theravance Biopharma Inc

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Drug Profiles

ARN-4079 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-1777 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Aclaris Therapeutics Inc, H1 2020
Pipeline by Arrien Pharmaceuticals LLC, H1 2020
Pipeline by Astellas Pharma Inc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Chipscreen Biosciences Ltd, H1 2020
Pipeline by Clevexel Pharma SAS, H1 2020
Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020
Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2020
Pipeline by Japan Tobacco Inc, H1 2020
Pipeline by KBP BioSciences Co Ltd, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by MYOS RENS Technology Inc, H1 2020
Pipeline by Oncostellae SL, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Portola Pharmaceuticals Inc, H1 2020
Pipeline by Sienna Biopharmaceuticals Inc, H1 2020
Pipeline by Simcere Pharmaceutical Group, H1 2020
Pipeline by Theravance Biopharma Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020

Dormant Products, H1 2020 (Contd..2), H1 2020
Dormant Products, H1 2020 (Contd..3), H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

Aclaris Therapeutics Inc

Arrien Pharmaceuticals LLC

Astellas Pharma Inc

Bristol-Myers Squibb Co

Chipscreen Biosciences Ltd

Clevexel Pharma SAS

Daewoong Pharmaceutical Co Ltd

Guangdong Zhongsheng Pharmaceutical Co Ltd

Japan Tobacco Inc

KBP BioSciences Co Ltd

Merck & Co Inc

MYOS RENS Technology Inc

Oncostellae SL

Pfizer Inc

Portola Pharmaceuticals Inc

Sienna Biopharmaceuticals Inc

Sincere Pharmaceutical Group

Theravance Biopharma Inc

I would like to order

Product name: Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/TCE5A0E507C0EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TCE5A0E507C0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970